Compare Gold Fields Limited (GFI) vs Natera Inc. Common Stock (NTRA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gold Fields Limited vs Natera Inc. Common Stock — how do they compare? Gold Fields Limited trades at $36.83 (market cap $32.04B), while Natera Inc. Common Stock trades at $392.78 (market cap $57.03B). The key difference: Natera Inc. Common Stock is the larger of the two by market cap, and Gold Fields Limited pays a 6.06% dividend while Natera Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Gold Fields Limited for 50 Days and Natera Inc. Common Stock for 0 Days on average.
| GFI | NTRA | |
|---|---|---|
Market Cap | $32.04B | $57.03B |
Volume | 3,910,984 | 1,131,157 |
Sector | Basic Materials | Health |
52-Week High | $61.52 | $425.64 |
52-Week Low | $31.25 | $179.42 |
Typical Hold Time | 50 Days | 0 Days |
Enterprise Value | $32.64B | $56.18B |
Dividend Yield | 6.06% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gold Fields (GFI) trades at $36.34, down 1.14% on the day, amid a bearish technical signal. The stock shows strong fundamentals with a P/E of 7.24, net income margin of 38.66%, and robust cash flow growth, with 2025 operating cash flow at $3.77 billion. Recent news highlights the company's pursuit of a combination with Northern Star, which was rejected, causing volatility. Earnings have been mixed, with three of the last four quarters missing expectations, but revenue and profitability trends are upward.
The outlook is cautiously optimistic due to solid financials and analyst support, with a consensus price target of $49.06 implying 35% upside. Key risks include execution of growth plans, gold price volatility, and integration challenges from potential M&A. Investor sentiment is divided, with technicals bearish but fundamentals strong, suggesting potential for recovery if operational targets are met.
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Gold Fields Limited
Gold Fields Ltd is a producer of gold and is a holder of gold reserves and resources in South Africa, Ghana, Australia and Peru. In Peru, the company also produces copper. The company is primarily involved in underground and surface gold and surface copper mining and silver and related activities, including exploration, extraction, processing and smelting. It conducts underground and surface mining operations at St. Ives, underground-only operations at Agnew, Granny Smith and South Deep and surface-only open pit mining at Damang, Tarkwa and Cerro Corona. The company's revenues are derived from the sale of gold that it produces.
Read more on GFI →About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →
